0000000000273788

AUTHOR

Katerina Okeke

0000-0002-0496-0514

showing 3 related works from this author

Do β3-adrenoceptor agonists cause urinary bladder smooth muscle relaxation by inhibiting acetylcholine release?

2017

The mechanisms leading to improvement of overactive bladder syndrome upon treatment with a β3-adrenoceptor agonist remain controversial. New research points to a role of inhibition of neuronal acetylcholine release. Whether this occurs by a direct effect on prejunctional β3-adrenoceptors or indirectly by formation of adenosine and activation of A1 adenosine receptors is being discussed.

0301 basic medicineAgonistSmooth muscle relaxationmedicine.medical_specialtyUrinary bladderPhysiologymedicine.drug_classbusiness.industryOveractive bladder syndromeAdenosine receptorAdenosine03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structureEndocrinologyInternal medicinemedicineβ3 adrenoceptorbusiness030217 neurology & neurosurgeryAcetylcholinemedicine.drugAmerican Journal of Physiology-Renal Physiology
researchProduct

Agonist‐induced desensitisation of β 3 ‐adrenoceptors: Where, when, and how?

2019

β3 -Adrenoceptor agonists have proven useful in the treatment of overactive bladder syndrome, but it is not known whether their efficacy during chronic administration may be limited by receptor-induced desensitisation. Whereas the β2 -adrenoceptor has phosphorylation sites that are important for desensitisation, the β3 -adrenoceptor lacks these; therefore, it had been assumed that β3 -adrenoceptors are largely resistant to agonist-induced desensitisation. While all direct comparative studies demonstrate that β3 -adrenoceptors are less susceptible to desensitisation than β2 -adrenoceptors, desensitisation of β3 -adrenoceptors has been observed in many models and treatment settings. Chimeric …

0301 basic medicinePharmacologyAgonistMessenger RNAmedicine.medical_specialtyCell typePhosphorylation sitesAdrenergic receptormedicine.drug_classbusiness.industryChinese hamster ovary cellTransfection03 medical and health sciences030104 developmental biology0302 clinical medicineEndocrinologyInternal medicinemedicinebusinessReceptor030217 neurology & neurosurgeryBritish Journal of Pharmacology
researchProduct

Desensitization of cAMP Accumulation via Human β3-Adrenoceptors Expressed in Human Embryonic Kidney Cells by Full, Partial, and Biased Agonists

2019

β3-Adrenoceptors couple not only to cAMP formation but, at least in some cell types, also to alternative signaling pathways such as phosphorylation of extracellular signal-regulated kinase (ERK). β3-Adrenoceptor agonists are used in long-term symptomatic treatment of the overactive bladder syndrome; it is only poorly understood which signaling pathway mediates the clinical response and whether it undergoes agonist-induced desensitization. Therefore, we used human embryonic kidney cells stably transfected with human β3-adrenoceptors to compare coupling of ligands with various degrees of efficacy, including biased agonists, to cAMP formation and ERK phosphorylation, particularly regarding des…

0301 basic medicineAgonistMAPK/ERK pathwaymedicine.drug_classmedicine.medical_treatmentdesensitization03 medical and health scienceschemistry.chemical_compoundpartial agonism0302 clinical medicinecAMPIsoprenalinemedicinePharmacology (medical)β3-adrenoceptorOriginal ResearchDesensitization (medicine)PharmacologyForskolinKinaselcsh:RM1-950extracellular signal-related kinaseCell biologylcsh:Therapeutics. Pharmacology030104 developmental biologybiased agonismchemistry030220 oncology & carcinogenesisPhosphorylationSignal transductionmedicine.drugFrontiers in Pharmacology
researchProduct